PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair

Chemico-Biological Interactions

Volumn 226, Issue , 2015, Pages 12-22

  Luo, Qingying ^a   Li, Yang ^a   Deng, Jianjun ^b   Zhang, Zunzhen ^a  

^a SICHUAN UNIVERSITY   (China)

^b Mianyang 404 Hospital   (China)

Author keywords

4 Amino 1,8 naphythalimide; Arsenic trioxide; Cyclin B1; G2 M phase checkpoint; PARP 1

Indexed keywords

4 AMINO 1,8 NAPHYTHALIMIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE 3; CYCLIN B1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 1 NAPHTHYLAMINE; 4-AMINO-1,8-NAPHTHALIMIDE; ENZYME INHIBITOR; NAPHTHALIMIDE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOARSENIC DERIVATIVE; OXIDE; PARP1 PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SINGLE STRANDED DNA BREAK; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY;

1-NAPHTHYLAMINE; ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CYCLIN B1; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; G2 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; NAPHTHALIMIDES; OXIDES; POLY(ADP-RIBOSE) POLYMERASES; QUINOLONES; UP-REGULATION;

EID: 84925371257     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.12.007     Document Type: Article

References (49)

1. Ardalan, B., Subbarayan, P.R., Ramos, Y., Gonzalez, M., Fernandez, A., Mezentsev, D., Reis, I., Duncan, R., Podolsky, L., Lee, K., Lima, M., Ganjei-Azar, P., A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin. Cancer Res. 16 (2010), 3019–3027.
2. Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., Lu, K., Schmutzler, R.K., Matulonis, U., Wickens, M., Tutt, A., Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376 (2010), 245–251.
3. Beishline, K., Azizkhan-Clifford, J., Interplay between the cell cycle and double-strand break response in Mammalian cells. Methods Mol. Biol. 1170 (2014), 41–59.
4. Bonati, A., Rizzoli, V., Lunghi, P., Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr. Pharm. Biotechnol. 7 (2006), 397–405.
5. Carbone, M., Rossi, M.N., Cavaldesi, M., Notari, A., Amati, P., Maione, R., Poly (ADP-ribosyl)ation is implicated in the G0–G1 transition of resting cells. Oncogene 27 (2008), 6083–6092.
6. Carnevale, J., Palander, O., Seifried, L.A., Dick, F.A., DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol. Cell. Biol. 32 (2012), 900–912.
7. Carrozza, M.J., Stefanick, D.F., Horton, J.K., Kedar, P.S., Wilson, S.H., PARP inhibition during alkylation-induced genotoxic stress signals a cell cycle checkpoint response mediated by ATM. DNA Repair (Amst) 8 (2009), 1264–1272.
8. Chaudhary, P., Sharma, R., Sahu, M., Vishwanatha, J.K., Awasthi, S., Awasthi, Y.C., 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway. J. Biol. Chem. 288 (2013), 20532–20546.
9. Csete, B., Lengyel, Z., Kadar, Z., Battyani, Z., Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. Pathol. Oncol. Res. 15 (2009), 47–53.
10. Damia, G., Garattini, S., The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev., 2014.
11. Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., Cascante, M., Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther. 138 (2013), 255–271.
12. Gerard, C., Goldbeter, A., Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 21643–21648.
13. Hao, L., Zhao, J., Wang, X., Wang, H., Wang, H., Xu, G., Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia. J. Pediatr. Hematol. Oncol. 35 (2013), e67–e70.
14. Heacock, M.L., Stefanick, D.F., Horton, J.K., Wilson, S.H., Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair (Amst) 9 (2010), 929–936.
15. Hirokawa, T., Shiotani, B., Shimada, M., Murata, K., Johmura, Y., Haruta, M., Tahara, H., Takeyama, H., Nakanishi, M., CBP-93872 inhibits NBS1-mediated ATR activation, abrogating maintenance of the DNA double-strand break-specific G2 checkpoint. Cancer Res. 74 (2014), 3880–3889.
16. Horton, J.K., Stefanick, D.F., Gassman, N.R., Williams, J.G., Gabel, S.A., Cuneo, M.J., Prasad, R., Kedar, P.S., Derose, E.F., Hou, E.W., London, R.E., Wilson, S.H., Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA Repair (Amst) 12 (2013), 774–785.
17. Horton, J.K., Stefanick, D.F., Kedar, P.S., Wilson, S.H., ATR signaling mediates an S-phase checkpoint after inhibition of poly (ADP-ribose) polymerase activity. DNA Repair (Amst) 6 (2007), 742–750.
18. Horton, J.K., Stefanick, D.F., Naron, J.M., Kedar, P.S., Wilson, S.H., Poly (ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. J. Biol. Chem. 280 (2005), 15773–15785.
19. Horton, J.K., Stefanick, D.F., Zeng, J.Y., Carrozza, M.J., Wilson, S.H., Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition. DNA Repair (Amst) 10 (2011), 225–234.
20. Horton, J.K., Wilson, S.H., Predicting enhanced cell killing through PARP inhibition. Mol. Cancer Res. 11 (2013), 13–18.
21. Javle, M., Curtin, N.J., The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105 (2011), 1114–1122.
22. Jelinic, P., Levine, D.A., New insights into PARP inhibitors’ effect on cell cycle and homology-directed DNA damage repair. Mol. Cancer Ther. 13 (2014), 1645–1654.
23. Jiang, X., Chen, C., Zhao, W., Zhang, Z., Sodium arsenite and arsenic trioxide differently affect the oxidative stress, genotoxicity and apoptosis in A549 cells: an implication for the paradoxical mechanism. Environ. Toxicol. Pharmacol. 36 (2013), 891–902.
24. Lai, Y., Zhao, W., Chen, C., Wu, M., Zhang, Z., Role of DNA polymerase beta in the genotoxicity of arsenic. Environ. Mol. Mutagen. 52 (2011), 460–468.
25. Lin, C.C., Hsu, C., Hsu, C.H., Hsu, W.L., Cheng, A.L., Yang, C.H., Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drugs 25 (2007), 77–84.
26. Liu, J.X., Zhou, G.B., Chen, S.J., Chen, Z., Arsenic compounds: revived ancient remedies in the fight against human malignancies. Curr. Opin. Chem. Biol. 16 (2012), 92–98.
27. Martinez-Bosch, N., Iglesias, M., Munne-Collado, J., Martinez-Caceres, C., Moreno, M., Guerra, C., Yelamos, J., Navarro, P., Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J. Pathol., 2014.
28. Mukhopadhyay, P., Horvath, B., Kechrid, M., Tanchian, G., Rajesh, M., Naura, A.S., Boulares, A.H., Pacher, P., Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic. Biol. Med. 51 (2011), 1774–1788.
29. Munoz-Gamez, J.A., Quiles-Perez, R., Ruiz-Extremera, A., Martin-Alvarez, A.B., Sanjuan-Nunez, L., Carazo, A., Leon, J., Oliver, F.J., Salmeron, J., Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. Cancer Lett. 301 (2011), 47–56.
30. Ogino, H., Nozaki, T., Gunji, A., Maeda, M., Suzuki, H., Ohta, T., Murakami, Y., Nakagama, H., Sugimura, T., Masutani, M., Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics, 8, 2007, 41.
31. Qin, Q., Cheng, H., Lu, J., Zhan, L., Zheng, J., Cai, J., Yang, X., Xu, L., Zhu, H., Zhang, C., Liu, J., Ma, J., Zhang, X., Dai, S., Sun, X., Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair. J. Hematol. Oncol., 7, 2014, 62.
32. Sakamaki, J., Daitoku, H., Yoshimochi, K., Miwa, M., Fukamizu, A., Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1. Biochem. Biophys. Res. Commun. 382 (2009), 497–502.
33. Sarszegi, Z., Bognar, E., Gaszner, B., Konyi, A., Gallyas, F. Jr., Sumegi, B., Berente, Z., BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol. Cell. Biochem. 365 (2012), 129–137.
34. Soica, C., Oprean, C., Borcan, F., Danciu, C., Trandafirescu, C., Coricovac, D., Crainiceanu, Z., Dehelean, C.A., Munteanu, M., The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl-gamma-cyclodextrin. Molecules 19 (2014), 4924–4940.
35. Solier, S., Zhang, Y.W., Ballestrero, A., Pommier, Y., Zoppoli, G., DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr. Cancer Drug Targets 12 (2012), 356–371.
36. Sousa, F.G., Matuo, R., Soares, D.G., Escargueil, A.E., Henriques, J.A., Larsen, A.K., Saffi, J., PARPs and the DNA damage response. Carcinogenesis 33 (2012), 1433–1440.
37. Sun, R.C., Board, P.G., Blackburn, A.C., Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol. Cancer, 10, 2011, 142.
38. Swindall, A.F., Stanley, J.A., Yang, E.S., PARP-1: friend or foe of DNA damage and repair in tumorigenesis?. Cancers (Basel) 5 (2013), 943–958.
39. Taira, N., Yamaguchi, T., Kimura, J., Lu, Z.G., Fukuda, S., Higashiyama, S., Ono, M., Yoshida, K., Induction of amphiregulin by p53 promotes apoptosis via control of microRNA biogenesis in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 717–722.
40. Theron, T., Böhm, L., Cyclin B1 expression in response to abrogation of the radiation-induced G2/M block in HeLa cells. Cell Prolif. 1998:31 (1998), 49–57.
41. Vineetha, V.P., Prathapan, A., Soumya, R.S., Raghu, K.G., Arsenic trioxide toxicity in H9c2 myoblasts–damage to cell organelles and possible amelioration with Boerhavia diffusa. Cardiovasc. Toxicol. 13 (2013), 123–137.
42. Wang, Y., Wei, Y., Zhang, H., Shi, Y., Li, Y., Li, R., Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase. Med. Oncol. 29 (2012), 1328–1334.
43. Wang, Z.Y., Chen, Z., Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111 (2008), 2505–2515.
44. Weil, M.K., Chen, A.P., PARP inhibitor treatment in ovarian and breast cancer. Curr. Probl. Cancer 35 (2011), 7–50.
45. Xia, J., Li, Y., Yang, Q., Mei, C., Chen, Z., Bao, B., Ahmad, A., Miele, L., Sarkar, F.H., Wang, Z., Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int. J. Mol. Sci. 13 (2012), 9627–9641.
46. Xia, Q., Cai, Y., Peng, R., Wu, G., Shi, Y., Jiang, W., The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Int. J. Oncol. 44 (2014), 735–744.
47. Yang, L., Huang, K., Li, X., Du, M., Kang, X., Luo, X., Gao, L., Wang, C., Zhang, Y., Zhang, C., Tong, Q., Huang, K., Zhang, F., Huang, D., Identification of poly (ADP-ribose) polymerase-1 as a cell cycle regulator through modulating Sp1 mediated transcription in human hepatoma cells. PLoS ONE, 8, 2013, e82872.
48. Zhao, X.Y., Yang, S., Chen, Y.R., Li, P.C., Dou, M.M., Zhang, J., Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PLoS ONE, 9, 2014, e98925.
49. Znojek, P., Willmore, E., Curtin, N.J., Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br. J. Cancer 111 (2014), 1319–1326.